Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05354622 · ClinicalTrials.gov registry record
Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)
A clinical trial of Movement Disorders and Motor Neuron Disease, sponsored by Boston Children's Hospital.
- Recruiting
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT05354622: Recruiting study of Movement Disorders and Motor Neuron Disease, sponsored by Boston Children's Hospital.
NCT05354622 is a study of Movement Disorders and Motor Neuron Disease that is actively recruiting participants, run by Boston Children's Hospital. The registered enrollment target is 200 participants, below the 1,060-participant average among 26 other Movement Disorders trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05354622, a study of Movement Disorders and Motor Neuron Disease, is actively recruiting participants, sponsored by Boston Children's Hospital.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the HSP Sequencing Initiative is to better understand the role of genetics in hereditary spastic paraplegia (HSP) and related disorders. The HSPs are a group of more than 80 inherited neurological diseases that share the common feature of progressive spasticity. Collectively, the HSPs present the most common cause of inherited spasticity and associated disability, with a combined prevalence of 2-5 cases per 100,000 individuals worldwide. In childhood-onset forms, initial symptoms are often non-specific and many children may not receive a diagnosis until progressive features are recognized, often leading to a significant diagnostic delay. Genetic testing in children with spastic paraplegia is not yet standard practice. In this study, the investigators hope to identify genetic factors related to HSP. By identifying different genetic factors, the investigators hope that over time we can develop better treatments for sub-categories of HSP based on cause.
Primary Outcome
Identifying genetic variants in patients with progressive spastic paraplegia
Conditions Studied
Study Locations (1)
Massachusetts
- Boston Children's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2022-04-25 |
| Est. Completion | 2027-04-29 |
What NCT05354622 shows while recruiting
NCT05354622 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 1,060-participant average among 26 other Movement Disorders trials with a reported enrollment target (81% lower).
The record links to 6 conditions, with Movement Disorders appearing as the primary indexed condition, and to 0 interventions.
NCT05354622 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05354622 about?
NCT05354622 is a clinical study titled "Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)". The purpose of the HSP Sequencing Initiative is to better understand the role of genetics in hereditary spastic paraplegia (HSP) and related disorders. The HSPs are a group of more than 80 inherited neurological diseases that share the common feature of progressive spasticity. Collectively, the HSPs...
What is the current status of trial NCT05354622?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2022-04-25. Estimated completion is 2027-04-29.
What conditions does trial NCT05354622 study?
This clinical trial studies the following conditions: Movement Disorders, Motor Neuron Disease, Neurodegenerative Diseases, Spasticity, Muscle, Pediatric Disorder.
Who is sponsoring clinical trial NCT05354622?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05354622 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Movement Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05354622's enrollment target sits among peer trials
200 9th of 26 higher than 18 of 26 other Movement Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Movement Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Retrospective Survey-based Multicenter Study to Delineate the Molecular and Phenotypic Spectrum of Epilepsy-dyskinesia Syndromes
RECRUITING
-
Neurophysiology of the Basal Ganglia, Thalamus, and Cerebellum in Patients With Movement Disorders
RECRUITING · NA
-
A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Severe Motor Complications
RECRUITING
-
Abbott DBS Post-Market Study of Outcomes for Indications Over Time
RECRUITING
-
Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures
RECRUITING
-
Analysis of Human Movement With Assistive Devices
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI